BFS
LGND icon

Bare Financial Services’s Ligand Pharmaceuticals LGND Stock Holding History

Bare Financial Services’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.6K Buy
53
+12
+29% +$2.37K ﹤0.01% 320
2025
Q4 		$7.75K Hold
41
– – ﹤0.01% 343
2025
Q3 		$7.26K Buy
41
+31
+310% +$4.61K ﹤0.01% 371
2025
Q2 		$1.14K Buy
10
+3
+43% +$321 ﹤0.01% 881
2025
Q1 		$736 Buy
+7
New +$792 ﹤0.01% 630

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Bare Financial Services's LGND Position: Q1 2026 in Review

Bare Financial Services increased its Ligand Pharmaceuticals (LGND) stake by 29% in Q1 2026, buying an estimated $2.37K and bringing the position to 53 shares worth $10.6K. The position accounts for ﹤0.01% of the portfolio, ranked #320.

Bare Financial Services first reported a position in LGND in Q1 2025 and has held it in 5 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Bare Financial Services held 53 shares of Ligand Pharmaceuticals worth $10.6K as of Q1 2026.
  • Bare Financial Services bought 12 Ligand Pharmaceuticals shares in Q1 2026, an estimated $2.37K.
  • Ligand Pharmaceuticals made up ﹤0.01% of Bare Financial Services's portfolio in Q1 2026, its #320 holding.
  • Bare Financial Services first reported a position in Ligand Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Bare Financial Services's 13F filing for Q1 2026, filed 14 May 2026.